Department of Medical Oncology, University Campus Bio-Medico, 00128 Rome, Italy.
Future Oncol. 2009 Dec;5(10):1675-84. doi: 10.2217/fon.09.130.
Biliary tract cancers (BTCs) include cholangiocarcinoma (intrahepatic, perihilar and extrahepatic), carcinoma of the gall bladder and ampullary carcinoma. In patients with advanced disease the prognosis is poor. There is not a consensus regarding treatment strategy. Chemotherapy has only limited efficacy. This review summarizes the new approaches for BTC patients and the rationale for targeted therapies. The prognostic factors and the molecular features of BTC are analyzed. The clinical trials evaluating the targeted agents are accurately described, especially those assessing the role of anti-EGFR and antiangiogenic drugs. The ongoing trials are also analyzed. In fact, only the results of these trials will establish which is the most effective agent or combination for this setting.
胆道癌（BTCs）包括胆管癌（肝内、肝门周围和肝外）、胆囊癌和壶腹癌。对于晚期疾病患者，预后较差。对于治疗策略尚未达成共识。化疗的疗效有限。本综述总结了 BTC 患者的新方法和靶向治疗的原理。分析了 BTC 的预后因素和分子特征。准确描述了评估靶向药物的临床试验，特别是那些评估抗 EGFR 和抗血管生成药物作用的临床试验。还分析了正在进行的试验。事实上，只有这些试验的结果才能确定哪种药物或联合治疗方案对这种情况最有效。
